Albert Pares
Albert Pares
Liver Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain
Verified email at
TitleCited byYear
Simplified criteria for the diagnosis of autoimmune hepatitis
EM Hennes, M Zeniya, AJ Czaja, A Parés, GN Dalekos, EL Krawitt, ...
Hepatology 48 (1), 169-176, 2008
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés, L Caballería, J Rodés
Gastroenterology 130 (3), 715-720, 2006
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
JM Mato, J Cámara, JF de Paz, L Caballería, S Coll, A Caballero, ...
Journal of hepatology 30 (6), 1081-1089, 1999
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
A Parés, R Planas, M Torres, J Caballería, JM Viver, D Acero, J Panés, ...
Journal of Hepatology 28 (4), 615-621, 1998
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: the RELIEF trial
R Bañares, F Nevens, FS Larsen, R Jalan, A Albillos, M Dollinger, ...
Hepatology 57 (3), 1153-1162, 2013
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
GM Hirschfield, A Mason, V Luketic, K Lindor, SC Gordon, M Mayo, ...
Gastroenterology 148 (4), 751-761. e8, 2015
Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case–control study
KK Søgaard, E Horváth-Puhó, H Grønbæk, P Jepsen, H Vilstrup, ...
The American journal of gastroenterology 104 (1), 96, 2009
Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial
E Cabré, P Rodrı́guez-Iglesias, J Caballerı́a, JC Quer, ...
Hepatology 32 (1), 36-42, 2000
Histological course of alcoholic hepatitis: influence of abstinence, sex and extent of hepatic damage
A Parés, J Caballería, M Bruguera, M Torres, J Rodés
Journal of hepatology 2 (1), 33-42, 1986
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury
A Parés, JM Barrera, J Caballería, G Ercilla, M Bruguera, L Caballería, ...
Hepatology 12 (6), 1295-1299, 1990
Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial
A Parés, L Caballería, J Rodés, M Bruguera, L Rodrigo, A García-Plaza, ...
Journal of hepatology 32 (4), 561-566, 2000
Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation
KM Boberg, A Bergquist, S Mitchell, A Pares, F Rosina, U Broome, ...
Scandinavian journal of gastroenterology 37 (10), 1205-1211, 2002
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ...
Nature genetics 45 (6), 670, 2013
Effects of long-term rifampicin administration in primary biliary cirrhosis
L Bachs, A Parés, M Elena, C Piera, J Rodés
Gastroenterology 102 (6), 2077-2080, 1992
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
RE Poupon, KD Lindor, A Parés, O Chazouillères, R Poupon, ...
Journal of hepatology 39 (1), 12-16, 2003
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study
WJ Lammers, HR Van Buuren, GM Hirschfield, HLA Janssen, P Invernizzi, ...
Gastroenterology 147 (6), 1338-1349. e5, 2014
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis
L Bachs, M Elena, A Parés, C Piera, J Rodés
The Lancet 333 (8638), 574-576, 1989
Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’
U Beuers, ME Gershwin, RG Gish, P Invernizzi, DEJ Jones, K Lindor, ...
Hepatology 62 (5), 1620-1622, 2015
Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy
WJ Lammers, GM Hirschfield, C Corpechot, F Nevens, KD Lindor, ...
Gastroenterology 149 (7), 1804-1812. e4, 2015
S‐adenosylmethionine treatment prevents carbon tetrachloride—induced S‐adenosylmethionine synthetase inactivation and attenuates liver injury
F Corrales, A Giménez, L Alvarez, J Caballería, MA Pajares, H Andreu, ...
Hepatology 16 (4), 1022-1027, 1992
The system can't perform the operation now. Try again later.
Articles 1–20